Article

Serological thresholds of risk reduction for infant group B streptococcus disease

2026-06-06

Abstract excerpt

Vaccines to prevent infant group B streptococcus (GBS) disease are advancing, with licensure likely based on safety and immunologic endpoints rather than clinical efficacy data. This approach requires robust, generalisable serological thresholds of risk reduction (SToRRs). We combined data from six case-control studies in Europe and Africa to define SToRRs for early-onset (EOD) and late-onset (LOD) GBS disease. Ac...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3826cb05-36eb-5586-9a39-4aa405efcb78
DOI: 10.64898/2026.05.29.26353453

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Serological thresholds of risk reduction for infant group B streptococcus diseaseDOI 10.64898/2026.05.29.26353453Read

Clinical and regulatory development strategies for GBS vaccines intended for maternal immunisation in low- and middle-income countriesSemantic proximity Read

Potential for Maternally Administered Vaccine for Infant Group B StreptococcusSemantic proximity Read

Association between anti-capsular IgG levels at birth and risk of invasive group B streptococcus disease in Finnish newborns: a retrospective case–control studySemantic proximity Read

An empirical Bayes method for serotype case-carrier ratios, with an application to Group B streptococcusSemantic proximity Read

Maternal immunisation against Group B Streptococcus: A global analysis of health impact and cost-effectivenessSemantic proximity Read

Group B Streptococcus: global incidence and vaccine developmentSemantic proximity Read

Antibody Correlates of Resilience to <i>Staphylococcus aureus</i> Disease and Recurrence in ChildrenSemantic proximity Read

Serotype-specific pneumococcal invasiveness: a global meta-analysis of paired estimates of disease incidence and carriage prevalenceSemantic proximity Read

Human systemic and mucosal immune responses support further exploration of a <i>Klebsiella pneumoniae</i> protein-based vaccineSemantic proximity Read

Using Dried Blood Spots for a Sero-Surveillance Study of Maternally Derived Antibody against Group B StreptococcusSemantic proximity Read

Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult womenSemantic proximity Read

Group B streptococcal disease and genotypes in Australian infants.Semantic proximity Read